Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

PLoS Medicine

Volumn 9, Issue 8, 2012, Pages

  Campbell, Thomas B ^a   Smeaton, Laura M ^b   Kumarasamy, N ^c   Flanigan, Timothy ^d   Klingman, Karin L ^e   Firnhaber, Cynthia ^f   Grinsztejn, Beatriz ^g   Hosseinipour, Mina C ^h   Kumwenda, Johnstone ⁱ   Lalloo, Umesh ^j   Riviere, Cynthia ^k   Sanchez, Jorge ^l   Melo, Marineide ^m   Supparatpinyo, Khuanchai ⁿ   Tripathy, Srikanth ^o   Martinez, Ana I ^e   Nair, Apsara ^p   Walawander, Ann ^p   Moran, Laura ^q   Chen, Yun ^b   Snowden, Wendy ^r   Rooney, James F ^s   Uy, Jonathan ^t   Schooley, Robert T ^u   de Gruttola, Victor ^b   Hakim, James Gita ^v   Swann, Edith ^e   Barnett, Ronald L ^q   Brizz, Barbara ^q   Delph, Yvette ^q   Gettinger, Nikki ^q   Mitsuyasu, Ronald T ^w   Eshleman, Susan ^x   Safren, Steven ^y   Fiscus, Susan A ^z   Andrade, Adriana ^x   Haas, David W ^aa   Amod, Farida ^j   Berthaud, Vladimir ^ab   Bollinger, Robert C ^x   Bryson, Yvonne ^ac   Celentano, David ^ad   Chilongozi, David ^ae   Cohen, Myron ^af   Collier, Ann C ^ag   Currier, Judith Silverstein ^ah   Cu Uvin, Susan ^ai   Eron, Joseph ^z   Flexner, Charles ^aj   Gallant, Joel E ^ak   Gulick, Roy M ^al   Hammer, Scott M ^am   Hoffman, Irving ^af   Kazembe, Peter ^an   Kumwenda, Newton ^ao   Lama, Javier R ^ap   Lawrence, Jody ^aq   Maponga, Chiedza ^v   Martinson, Francis ^ae   Mayer, Kenneth ^d   Nielsen, Karin ^ac   Pendame, Richard B ^ar   Ramratnam, Bharat ^d   Sanne, Ian ^f   Severe, Patrice ^as   Sirisanthana, Thira ⁿ   Solomon, Suniti ^c   Tabet, Steve ^ag   Taha, Taha ^ad   van der Horst, Charles ^z   Wanke, Christine ^at   Gormley, Joan ^au   Marcus, Cheryl J ^af   Putnam, Beverly ^av   Ntshele, Smanga ^ar   Loeliger, Edde ^aw   Pappa, Keith A ^r   Webb, Nancy ^p   Shugarts, David L ^av   Winters, Mark A ^ax   Descallar, Renard S ^s   Steele, Joseph ^s   Wulfsohn, Michael ^s   Said, Farideh ^s   Chen, Yue ^s   Martin, John C ^s   Bischofberger, Norbert ^s   Cheng, Andrew ^s   Jaffe, Howard ^s   Sharma, Jabin ^ay   Poongulali, S ^c   Cardoso, Sandra Wagner ^g   Faria, Deise Lucia ^g   Berendes, Sima ⁱ   Burke, Kelly ^ar   Mngqibisa, Rosie ^j   Kanyama, Cecelia ^h   Kayoyo, Virginia ^h   Samaneka, Wadzanai P ^v   Chisada, Anthony ^v   Faesen, Sharla ^f   Chariyalertsak, Suwat ⁿ   Santos, Breno ^az   Lira, Rita Alves ^az   Joglekar, Anjali A ^o   la Rosa, Alberto ^l   Infante, Rosa ^ap   Jain, Mamta ^ba   Petersen, Tianna ^ba   Godbole, Sheela ^bb   Dhayarkar, Sampada ^bb   Feinberg, Judith ^bc   Baer, Jenifer ^bc   Pollard, Richard B ^bd   Asmuth, David ^bd   Gangakhedkar, Raman R ^bb   Gaikwad, Asmita ^bb   Ray, M Graham ^be   Basler, Cathi ^be   Para, Michael F ^bf   Watson, Kathy J ^bf   Taiwo, Babafemi ^bg   McGregor, Donna ^bg   Balfour, Henry H ^bh   Mullan, Beth ^bh   Kim, Ge Youl ^bi   Klebert, Michael K ^bi   Cox, Gary Matthew ^bj   Silberman, Martha ^bj   Mildvan, Donna ^bk   Revuelta, Manuel ^bk   Tashima, Karen T ^au   Patterson, Helen ^au   Geiseler, P Jan ^bl   Santos, Bartolo ^bl   Daar, Eric S ^ah   Lopez, Ruben ^ah   Frarey, Laurie ^af   Currin, David ^af   Haas, David H ^aa   Bailey, Vicki L ^bm   Tebas, Pablo ^bn   Zifchak, Larisa ^bm   Noel Connor, Jolene ^bn   Torres, Madeline ^bn   Sha, Beverly E ^bo   Fritsche, Janice M ^bo   Cespedes, Michelle ^bp   Forcht, Janet ^bp   O'Brien, William A ^bq   Mogridge, Cheryl ^bq   Hurley, Christine ^br   Corales, Roberto ^br   Palmer, Maria ^w   Adams, Mary ^bs   Luque, Amneris ^bs   Lopez Detres, Luis ^bt   Stroberg, Todd ^bt   more..

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^d BROWN UNIVERSITY   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g Funda??o Oswaldo Cruz   (Brazil)

^h KAMUZU CENTRAL HOSPITAL   (Malawi)

ⁱ UNIVERSITY OF MALAWI   (Malawi)

^j UNIVERSITY OF KWAZULU NATAL   (South Africa)

^k Institut Nacional de laboratoire et de Recherches   (Haïti)

^l ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

^m HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

ⁿ CHIANG MAI UNIVERSITY   (Thailand)

^o NATIONAL AIDS RESEARCH INSTITUTE   (India)

^p FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^q SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^r GLAXOSMITHKLINE   (United States)

^s GILEAD SCIENCES   (United States)

^t BRISTOL MYERS SQUIBB   (United States)

^u UNIVERSITY OF CALIFORNIA   (United States)

^v UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^w UNIVERSITY OF CALIFORNIA   (United States)

^x JOHNS HOPKINS UNIVERSITY   (United States)

^y HARVARD MEDICAL SCHOOL   (United States)

^z UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^aa VANDERBILT UNIVERSITY   (United States)

^ab VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^ac UNIVERSITY OF CALIFORNIA   (United States)

^ad JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^ae UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^af UNIVERSITY OF NORTH CAROLINA   (United States)

^ag UNIVERSITY OF WASHINGTON   (United States)

^ah UNIVERSITY OF CALIFORNIA   (United States)

^ai BROWN UNIVERSITY   (United States)

^aj JOHNS HOPKINS HOSPITAL   (United States)

^ak JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^al Cornell University   (United States)

^am New York Presbyterian Hospital Columbia University Medical Center   (United States)

^an Baylor College of Medicine Abbott Fund Children's Clinical Centre of Excellence   (Malawi)

^ao Johns Hopkins Project   (Malawi)

^ap Investigaciones Medicas en Salud INMENSA   (Peru)

^aq UNIVERSITY OF CALIFORNIA   (United States)

^ar The Cornell Clinical Trials Unit ^*

^as Research Institute for Health Sciences   (Haïti)

^at TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^au MIRIAM HOSPITAL   (United States)

^av UNIVERSITY OF COLORADO   (United States)

^aw Clinical Development and Medical Affairs   (United Kingdom)

^ax STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^ay YRG Centre for AIDS Research and Education   (India)

^az Hospital Conceicao   (Brazil)

^ba UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^bb Nimbkar Agricultural Research Institute   (India)

^bc UNIVERSITY OF CINCINNATI   (United States)

^bd UNIVERSITY OF CALIFORNIA   (United States)

^be UNIVERSITY OF COLORADO HOSPITAL   (United States)

^bf OHIO STATE UNIVERSITY   (United States)

^bg NORTHWESTERN UNIVERSITY   (United States)

^bh UNIVERSITY OF MINNESOTA   (United States)

^bi WASHINGTON UNIVERSITY   (United States)

^bj DUKE UNIVERSITY MEDICAL CENTER   (United States)

^bk BETH ISRAEL MEDICAL CENTER   (United States)

^bl UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^bm HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^bn Och Spine at New York Presbyterian Hospitals   (United States)

^bo RUSH UNIVERSITY MEDICAL CENTER   (United States)

^bp NEW YORK UNIVERSITY   (United States)

^bq UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^br GEORGETOWN UNIVERSITY   (United States)

^bs UNIVERSITY OF ROCHESTER   (United States)

^bt Department of Obstetrics Gynecology   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE; VIRUS RNA;

ADULT; ARTICLE; CACHEXIA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KIDNEY DISEASE; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NEUROLOGIC DISEASE; NEUTROPENIA; OPEN STUDY; PREGNANCY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; TREATMENT OUTCOME; TUBERCULOSIS; WEIGHT REDUCTION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INTERNATIONALITY; MALE; MYCOBACTERIUM TUBERCULOSIS; PREGNANCY; TIME FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84865566725     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001290     Document Type: Article

References (32)

1. World Health Organization (2010) Treatment 2.0: Is this the future of treatment? World Health Organization. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2010/20100713_outlook_treatment2_0_en.pdf. Accessed 8 August 2011.
2. Hirnschall G, Schwartlander B, (2011) Treatment 2.0: catalysing the next phase of scale-up. Lancet 378: 209-211.
3. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: World Health Organization.
4. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, et al. (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 341: 1865-1873.
5. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, et al. (2004) Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 350: 1850-1861.
6. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354: 251-260.
7. Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, et al. (2004) Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 36: 1011-1019.
8. Malan DR, Krantz E, David N, Wirtz V, Hammond J, et al. (2008) Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 47: 161-167.
9. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S, (2003) Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 32: 18-29.
10. Berenguer J, Gonzalez J, Ribera E, Domingo P, Santos J, et al. (2008) Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Clin Infect Dis 47: 1083-1092.
11. Molina JM, Journot V, Morand-Joubert L, Yeni P, Rozenbaum W, et al. (2005) Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. J Infect Dis 191: 830-839.
12. Molina JM, Journot V, Furco A, Palmer P, De CN, et al. (2007) Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial). Antivir Ther 12: 417-422.
13. Sanchez-Conde M, Palacios R, Sanz J, Rodriguez-Novoa S, Rivas P, et al. (2007) Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study. AIDS Res Hum Retroviruses 23: 1237-1241.
14. Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, et al. (2004) Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 292: 180-189.
15. Division of AIDS (2004; 2010) Table for grading the severity of adult and pediatric adverse events Available: http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf. Accessed 12 January 2011.
16. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (2002) Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements- clinical considerations for accelerated and traditional approval. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf. Accessed 13 October 2010.
17. Xu X, Tian L, Wei LJ, (2003) Combining dependent tests for linkage or association across multiple phenotypic traits. Biostatistics 4: 223-229.
18. Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, et al. (2004) Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis 189: 1176-1184.
19. King JR, Kakuda TN, Paul S, Tse MM, Acosta EP, et al. (2007) Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers. J Clin Pharmacol 47: 201-208.
20. Pai MP, Schriever CA, az-Linares M, Novak RM, Rodvold KA, (2004) Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy 24: 592-599.
21. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, et al. (1987) The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 317: 192-197.
22. Jacobson MA, Liu RC, Davies D, Cohen PT, (1997) Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection. Arch Intern Med 157: 1825-1831.
23. Moore RD, Keruly JC, Chaisson RE, (1995) Neutropenia and bacterial infection in acquired immunodeficiency syndrome. Arch Intern Med 155: 1965-1970.
24. Hermans P, Sommereijns B, Van CN, Clumeck N, (1999) Neutropenia in patients with HIV infection: a case control study in a cohort of 1403 patients between 1982 and 1993. J Hematother Stem Cell Res 8 (Suppl 1):: S23-S32.
25. Kuritzkes DR, Parenti D, Ward DJ, Rachlis A, Wong RJ, et al. (1998) Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. AIDS 12: 65-73.
26. Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, et al. (2006) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 43: 535-540.
27. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2010) Global report: UNAIDS report on the global AIDS epidemic 2010. Available: http://www.unaids.org/globalreport/Global_report.htm. Accessed 14 September 2011.
28. d'Arminio MA, Gonzalez L, Haberl A, Sherr L, Ssanyu-Sseruma W, et al. (2010) Better mind the gap: addressing the shortage of HIV-positive women in clinical trials. AIDS 24: 1091-1094.
29. Moore RD, Fortgang I, Keruly J, Chaisson RE, (1996) Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 101: 34-40.
30. Currier JS, Spino C, Grimes J, Wofsy CB, Katzenstein DA, et al. (2000) Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The AIDS Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 24: 316-324.
31. Clark R, (2005) Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf 28: 1075-1083.
32. Nielsen-Saines K, Komarow L, Cu-Uvin S, Jourdain G, Klingman K, et al. (2012) Assessment of safety and toxicity following maternal antiretroviral exposure in infants born To HIV-infected women enrolled in antiretroviral treatment protocols in diverse areas of the world. Eighteen month results of AIDS Clinical Trials Group (ACTG) Study 5190/Pediatric AIDS Clinical Trials Group (PACTG) 1054. Pediatrics 129: e1525-e1532.